Liquid Biopsy Market 2020 Rapidly Growing Across the Worldwide
Liquid biopsy is a non-invasive procedure which enables doctors to identify the information regarding the tumor using a blood sample. This technique is mainly used to diagnose chronic diseases such as cancer. It is also used to monitor the effect of treatment on cancer patients’ multiple times.
The growth of the liquid biopsy market is primarily driven by increasing prevalence of cancer, growing adoption of non-invasive diagnostic, and monitoring techniques and increasing preference of personalized medicines. In addition, technological advancement, increasing government initiatives to develop healthcare infrastructure and large availability funding’s for research and development for liquid biopsy is likely to contribute to the growth of liquid biopsy market during the forecast period. On the other hand, uncertain reimbursement, and regulation; and availability of alternative technique might hamper the liquid biopsy market to a certain extent throughout the forecast period.
North America accounted for nearly 32% share of the global liquid biopsy market in 2018 and is expected to dominate the market throughout the forecast period followed by Europe. The growth of this region is attributed to the high incidence of cancer, easy accessibility and growing adoption of advanced diagnostic techniques. In addition, growing public and private funding to support research activities in the field of liquid biopsy contributes to the growth of this segment throughout the forecast periods.
Asia-Pacific region is expected to grow at the fastest growing CAGR during the forecast period. The growth of this segment is attributed to the increasing government initiatives, growing prevalence cancer etc. Countries like China, India, and Japan are the major contributors to the growth of Asia-pacific region liquid biopsy market.
Company Profiles and Competitive Intelligence:
The major players operating in the global liquid biopsy market are Bio-Rad Laboratories Inc. (US), Menarini Silicon Biosystems (Italy), Trovagene, Inc. (US),RainDance Technologies, Inc. (US), QIAGEN N.V. (Netherlands), Genomic Health, Inc. (US),Roche Diagnostics (US), Myriad Genetics, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Guardant Health, Inc. (US), Biocept, Inc. (US), and MDx Health SA (US).among others.
Source inforgrowth.com/report/6523423/liquid-biopsy-market
About InForGrowth:
We are a market-intelligence company formed with the objective of providing clients access to the most relevant and accurate research content for their growth needs. At InForGrowth, we understand Research requirements and help a client in taking informed business critical decisions. Given the complexities and interdependencies of market-intelligence, there is always more than one source to explore and arrive at the right answer. Through our smart search feature and our reliable and trusted publishing partners, we are paving way for a more simplified and relevant research.
